GlassScriptPhysician profile
Madaelil Thomas
NPI 1417950346
$781.80
in general payments reported to CMS, 2019-2025
11 companies · $84.91 in 2025
The $84.91 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $165 · 2022: $21.70 · 2023: $390 · 2024: $120 · 2025: $84.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $594.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.25 | 2023-2025 | Jardiance, Tradjenta |
| Medtronic, INC. | $128.37 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $124.57 | 2023 | Camzyos |
| Lilly USA, LLC | $46.42 | 2023 | Mounjaro |
| Abbott Laboratories | $36.90 | 2021 | |
| Novo Nordisk INC | $32.26 | 2023-2024 | Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $27.94 | 2023 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Amgen INC. | $15.59 | 2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $13.42 | 2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $13.38 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madaelil Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.